BigHat Biosciences Stock / BioTech & PharmaFounded: 2019

BigHat Biosciences operates out of San Mateo, California and creates antibody therapies using machine learning technologies. The company integrates wet labs into their approach to find better treatments and therapies for patients suffering from some of the most challenging diseases. Through the ML technologies it uses, BigHat Biosciences mission is to create new generations of safer, more effective treatments, at a faster pace.

Register To Buy and Sell Shares

For more details on financing and valuation for BigHat Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access BigHat Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BigHat Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Mark DePristo
Chief Executive Officer & Co-Founder
Peyton Greenside
Chief Security Officer & Co-Founder
Liz Schwarzbach
Chief Business Officer
Eddie Abrams
Vice President, Engineering

Board Members

Francisco Gimenez, PhD
Partner, 8VC
Vineeta Agarwala, MD PhD
General Partner, a16z
Steve Kafka, PhD
Managing Partner, Section 32
Rob Chess

Frequently Asked Questions About BigHat Biosciences’ Stock

Can you buy BigHat Biosciences’ stock?
BigHat Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy BigHat Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell BigHat Biosciences’ stock?
Yes, you can sell stock of a private company like BigHat Biosciences. Forge can help you sell your BigHat Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is BigHat Biosciences’ stock price?
BigHat Biosciences is a privately held company and therefore does not have a public stock price. However, you may access BigHat Biosciences’ private market stock price with Forge Data.
What is BigHat Biosciences’ stock ticker symbol?
BigHat Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Firm Advises BigHat Biosciences on Research Collaboration with AbbVie
BigHat Biosciences is set to receive an upfront payment of $30 million and potentially up to $325 million in aggregate R&D milestones from AbbVie Inc. This follows a research partnership announcement between the two companies to develop next-generation therapeutic antibodies in oncology and neuroscience. This agreement also leaves room for further commercial milestones and tiered royalties on net sales.
AI-Created Antibodies Drive Innovation at BigHat Biosciences
BigHat Biosciences is leveraging AI and machine learning to revolutionize the design and development of next-generation antibodies for therapeutic applications. The company's Milliner platform integrates AI with wet lab technologies to create antibodies faster and more efficiently. BigHat's approach is expected to produce better performing synthetic compounds and accelerate drug discovery, thus potentially transforming the pharmaceutical industry.
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.